ESR1 and breast cancer: These results are consistent with the findings that several mechanisms are associated with E2 exposure, including rapid activation of IGF-IR and MAP kinase, a nongenomic process observed in estrogen-responsive breast cancer cell lines [39], which could lead to ERα activation at serine 118 [14, 28].